Actively Recruiting
Palliative Spatially Fractionated (GRID) Radiotherapy Using Intensity Modulated Proton Therapy
Led by Washington University School of Medicine · Updated on 2026-03-06
24
Participants Needed
1
Research Sites
215 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Spatially fractionated radiotherapy (SFRT or GRID) addresses some limitations of traditional stereotactic body radiation therapy by relying on beam collimation to create high-dose "peaks" and intervening low-dose "valleys" throughout the target volume. Standard palliative radiotherapy regimens provide limited durability of response, and there are challenges with delivery to large tumors or in previously irradiated fields. In this study, Proton GRID radiotherapy will be used to deliver three-fraction palliative radiotherapy to patients with tumors needing palliative radiation. The safety and efficacy of this approach will be assessed. It is hypothesized that GRID is highly effective, immunogenic, and associated with low rates of toxicity.
CONDITIONS
Official Title
Palliative Spatially Fractionated (GRID) Radiotherapy Using Intensity Modulated Proton Therapy
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Histologically or cytologically confirmed cancer diagnosis.
- Planning to undergo palliative radiotherapy to unresectable or metastatic target lesion 5 4.5 cm in any dimension as measured with radiographic imaging or clinical exam.
- ECOG performance status 5 3.
- At least 18 years of age.
- Willingness to use adequate contraception for women of childbearing potential and men prior to and during study participation, and for men 6 months after study completion.
- Ability to understand and sign informed consent or have a legally authorized representative do so.
You will not qualify if you...
- Tumors needing urgent surgery, such as life-threatening bleeding or high risk for fracture amenable to surgery.
- Superficial target lesion 5 1 cm deep to skin who had prior irradiation to the same area.
- Currently receiving cytotoxic cancer therapy or VEGF inhibitors overlapping with proton GRID treatment.
- Pregnant women; women of childbearing potential must have a negative pregnancy test within 20 days before enrollment.
- HIV patients with CD4+ counts < 350 cells/mcL or recent AIDS-defining infection within 12 months.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Washington University School of Medicine
St Louis, Missouri, United States, 63110
Actively Recruiting
Research Team
A
Anthony Apicelli, M.D.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here